This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Biotech Stocks Under $10 Set to Soar

Navidea Biopharmaceuticals

Another under-$10 stock in the biotechnology and drugs complex that looks ready to trigger a near-term breakout trade is Navidea Biopharmaceuticals (NAVB - Get Report), which is focused on the development and commercialization of precision diagnostic agents. This stock has soared over 60% in just the last three months.

If you take a look at the chart for Navidea Biopharmaceuticals, you'll see that this stock triggered a major breakout back in late June once it smashed through some previous overhead resistance at $3.47 to 3.55 a share with monster upside volume. Following that breakout, shares of NAVB soared to its recent high near $4.45 a share. During that monster run, the upside volume for NAVB has been off the charts for most of June and July. Since hitting that high at $4.45, shares of NAVB have started to move sideways between $4.40 and $4.09 a share. A move outside of that range will now setup the next major trend for NAVB.

>>Hot Biotech Stocks Traded by Hedge Funds

Traders should now look for long-biased trades in NAVB if it can manage to trigger a breakout trade above some near-term overhead resistance at $4.45 a share with high volume. Look for volume off a sustained move or close above $4.45 that registers near or above its three-month average action of 548,951 shares. If that breakout triggers soon, then NAVB will have a great chance of re-testing and possibly taking out its 2011 high of $5.48 a share.

If you're in the bull camp on NAVB, then one could look to buy this stock off any weakness and simply anticipate the breakout. If you get long off weakness, then use a stop at around $4.09 or even down to $3.80 a share. I would prefer to get long off strength once NAVB takes out $4.45 with high volume. If you get long off strength, then use a stop just below $4.09 a share in case it's not ready to launch just yet.

Make note that the current short interest as a percentage of the float for NAVB is extremely high at 17.4%. This company has a major catalyst on the horizon, since it will meet with the FDA on September 10 for the possible approval of its drug candidate Lymphoseek. This product is used for intraoperative lymphatic mapping. We could easily see NAVB short-squeeze huge right into that PDUFA date, so keep this one on watch.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DEPO $22.67 0.00%
HALO $13.93 0.00%
NAVB $1.68 0.00%
SQNM $3.90 0.00%
AAPL $123.25 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs